Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015, Article ID 414378, 6 pages
http://dx.doi.org/10.1155/2015/414378
Research Article

Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis

1Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India
2Department of Medicine, All India Institute of Medical Sciences, New Delhi 110029, India

Received 22 July 2014; Revised 4 December 2014; Accepted 12 December 2014

Academic Editor: Prasoon Gupta

Copyright © 2015 Shyam Sundar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. E. Zijlstra, A. M. Musa, E. A. G. Khalil, I. M. El Hassan, and A. M. El-Hassan, “Post-kala-azar dermal leishmaniasis,” The Lancet Infectious Diseases, vol. 3, no. 2, pp. 87–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Sundar, F. Rosenkaimer, M. K. Makharia et al., “Trial of oral miltefosine for visceral leishmaniasis,” The Lancet, vol. 352, no. 9143, pp. 1821–1823, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Sundar, T. K. Jha, C. P. Thakur et al., “Oral miltefosine for Indian visceral leishmaniasis,” The New England Journal of Medicine, vol. 347, no. 22, pp. 1739–1746, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. D. Mondal, K. N. Nasrin, M. M. Huda et al., “Enhanced case detection and improved diagnosis of PKDL in a Kala-azar-endemic area of Bangladesh,” PLoS Neglected Tropical Diseases, vol. 4, no. 10, article e832, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. R. Maurya, R. K. Singh, B. Kumar, P. Salotra, M. Rai, and S. Sundar, “Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure,” Journal of Clinical Microbiology, vol. 43, no. 7, pp. 3038–3041, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. Cancer Therapy Evaluation Program, Common Toxicity Criteria of the DCTD, NCI, NIH, DHHS. Version 2.0, 1999.
  7. C. P. Thakur, S. Narain, N. Kumar, S. M. Hassan, D. K. Jha, and A. Kumar, “Amphotericin B is superior to sodium antimony gluconate in the treatment of Indian post-kala-azar dermal leishmaniasis,” Annals of Tropical Medicine and Parasitology, vol. 91, no. 6, pp. 611–616, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Sundar, D. Mondal, S. Rijal et al., “Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal—the challenges for diagnosis and treatment,” Tropical Medicine and International Health, vol. 13, no. 1, pp. 2–5, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. C. P. Thakur and K. Kumar, “Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis,” Indian Journal of Medical Research, vol. 91, pp. 144–148, 1990. View at Google Scholar · View at Scopus
  10. V. Ramesh, G. K. Katara, S. Verma, and P. Salotra, “Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis,” British Journal of Dermatology, vol. 165, no. 2, pp. 411–414, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. S. Sundar, A. Singh, M. Rai et al., “Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use,” Clinical Infectious Diseases, vol. 55, no. 4, pp. 543–550, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus